Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

[Influence of donor activating or inhibitory KIR on prognosis of unmanipulated allogeneic hematopoietic stem cell transplantation].

Liang ZY, Ren HY, Cen XN, Qiu ZX, Wang LH, Ou JP, Li Y, Wang MJ, Wang WS, Xu WL, Dong YJ, Yin Y, Sun YH.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Feb;21(1):155-60. doi: 10.7534/j.issn.1009-2137.2013.01.032. Chinese.

PMID:
23484711
2.

Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.

Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ.

Biol Blood Marrow Transplant. 2010 Apr;16(4):533-42. doi: 10.1016/j.bbmt.2009.11.022.

3.

HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, Petersdorf E, Dupont B, Hsu KC.

N Engl J Med. 2012 Aug 30;367(9):805-16. doi: 10.1056/NEJMoa1200503.

4.

[Effects of killer immunoglobulin-like receptor and human leukocyte antigen class I ligand on the prognosis of related donor hematopoietic stem cell transplantation].

Wang H, Zhai WJ, Wang HH, He Y, Zhou Z, Zhao YX, Zhai WH, Zhang RL, Wang M, Feng SZ, Han MZ.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009 Oct;31(5):533-7. Chinese.

5.
6.

[The effect of inhibitory and activating natural killer cell immunoglobulin receptor on haplo-identical hematopoietic stem cell transplantation].

Zhang X, Zhang YL, Wang JL, Tong CR, Cai P, Liu HX, Wang JB, Cao XY, Ying YM, Wu T.

Zhonghua Xue Ye Xue Za Zhi. 2011 Aug;32(8):525-8. Chinese.

PMID:
22338174
7.
8.

[Distribution of immunoglobulin like receptor gene in Han population in China and the impact thereof on the HLA-identical sibling hematopoietic stem cell transplantation].

Dou LP, DA WM, Zhao DD, Wang C, Lu XC, Kang HY, Yan P, Wang FF, Zhu HY, Li HH, Gao CJ, Yu L.

Zhonghua Yi Xue Za Zhi. 2007 Nov 27;87(44):3111-4. Chinese.

PMID:
18269867
9.

[Impact of donor KIR2DS5 genotype on outcome following haploidentical hematopoietic stem cell transplantation].

Wang H, He Y, Wang HH, Wang M, Zhai WJ, Zhou Z, Zhang RL, Zhai WH, Feng SZ, Han MZ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Feb;16(1):111-5. Chinese.

PMID:
18315912
10.

Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality.

Mancusi A, Ruggeri L, Urbani E, Pierini A, Massei MS, Carotti A, Terenzi A, Falzetti F, Tosti A, Topini F, Bozza S, Romani L, Tognellini R, Stern M, Aversa F, Martelli MF, Velardi A.

Blood. 2015 May 14;125(20):3173-82. doi: 10.1182/blood-2014-09-599993.

11.

Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.

Nowak J, Kościńska K, Mika-Witkowska R, Rogatko-Koroś M, Mizia S, Jaskuła E, Polak M, Mordak-Domagała M, Lange J, Gronkowska A, Jędrzejczak WW, Kyrcz-Krzemień S, Markiewicz M, Dzierżak-Mietła M, Tomaszewska A, Nasiłowska-Adamska B, Szczepiński A, Hałaburda K, Hellmann A, Czyż A, Gil L, Komarnicki M, Wachowiak J, Barańska M, Kowalczyk J, Drabko K, Goździk J, Wysoczańska B, Bogunia-Kubik K, Graczyk-Pol E, Witkowska A, Marosz-Rudnicka A, Nestorowicz K, Dziopa J, Szlendak U, Warzocha K, Lange A; Polish Donor-Recipient Matching Study Group..

Biol Blood Marrow Transplant. 2015 May;21(5):829-39. doi: 10.1016/j.bbmt.2015.01.018.

12.

KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched Transplantation in Patients with Donors with KIR Gene Haplotype A.

Wu X, Yao Y, Bao X, Zhou H, Tang X, Han Y, Ma X, Liu Y, Chen J, Zhou H, Jing S, Gu B, Xu Y, Sun A, He J, Wu D.

Biol Blood Marrow Transplant. 2016 Feb;22(2):220-5. doi: 10.1016/j.bbmt.2015.10.004.

PMID:
26476204
13.

Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.

Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, Romeo E, Cognet C, Martinetti M, Maccario R, Mingari MC, Vivier E, Moretta L, Locatelli F, Moretta A.

Blood. 2009 Mar 26;113(13):3119-29. doi: 10.1182/blood-2008-06-164103.

14.
15.

[The prognostic analysis of KIR ligand mismatch in HLA-mismatched hematopoietic stem cell transplantation].

Zhao XY, Huang XJ, Liu KY, Xu LP, Liu DH.

Zhonghua Xue Ye Xue Za Zhi. 2008 May;29(5):316-20. Chinese.

PMID:
18844069
16.

[Relationship between the genetic background of donor KIR recipient HLA and the outcomes in HLA-identical sibling HSCT].

Ma HJ, Yin XL, Guo KY, Xiao LL, Ye X.

Zhonghua Xue Ye Xue Za Zhi. 2006 Feb;27(2):91-4. Chinese.

PMID:
16732960
17.

Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders.

Chen C, Busson M, Rocha V, Appert ML, Lepage V, Dulphy N, Haas P, Socié G, Toubert A, Charron D, Loiseau P.

Bone Marrow Transplant. 2006 Sep;38(6):437-44.

PMID:
16892071
18.

Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.

Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, Marsh SG, Guethlein LA, Parham P, Miller JS, Weisdorf DJ.

Blood. 2009 Jan 15;113(3):726-32. doi: 10.1182/blood-2008-07-171926.

19.

Impact of incompatible killer cell immunoglobulin-like receptor and its ligand on the outcome of haploidentical bone marrow transplantation.

Duan LN, Han HX, Liu J, Yan HM, Zhu L, Xue M, Ding L, Zhu PY, Wang HX, Ji SQ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Aug;15(4):809-15.

PMID:
17708809
20.

[Study on the behavior of NK cell KIRs of donor/recipient pairs in HLA matched unrelated allo-HSCT].

Bao XJ, He J, Chen ZX, Wu DP, Yao L, Yuan XN, Cen JN, Qiu QC, Di WY, Zhang H, Zhang J, Zhou XH, Xu HX.

Zhonghua Xue Ye Xue Za Zhi. 2007 Aug;28(8):510-3. Chinese.

PMID:
18078124
Items per page

Supplemental Content

Support Center